Plain-English translation of NCT03612726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that follows patients who have been diagnosed with unresectable hepatocellular carcinoma (advanced liver cancer that cannot be surgically removed) to understand how long they survive and what factors affect their outcomes. The study will collect information from 5,000 patients across the Asia Pacific region under real-world clinical conditions — meaning patients receiving their normal, standard care rather than a new experimental treatment.
Liver cancer is a serious disease that causes many deaths worldwide, with the highest rates in East Asia. By studying how patients with advanced liver cancer fare in real-world practice settings, researchers hope to better understand survival patterns and improve care for future patients in the region.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to access and review your medical records and follow-up information related to your liver cancer diagnosis and treatment. There are no new medications to take or special procedures required — the study simply observes and documents the care you are already receiving from your doctors. Your participation helps researchers better understand how patients with your condition fare over time under standard medical care.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Hong Kong
Japan
Collaborators
Tokyo University
Enrollment target
~5,000 participants
Started
July 2018
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Danny Wang, PhD
Tokyo University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.